Evaluate Pharma

Q1 2026 biopharma: momentum is back… but caution is still driving decisions. -M&A up 32% QoQ -IPOs hit $1.81B (faded by March) -VC steady at $7.94B Capital is available, but deployed more selectively than ever. See where conviction is building: vist.ly/545sw

Great forecasting goes beyond the numbers. vist.ly/53zbm As Sheila Li explains, the strongest forecasts take a holistic approach — bringing together rigorous models, expert judgment, and high‑quality data to support smarter decision‑making across the pharma lifecycle.

Forecasting is more than a numbers game. vist.ly/53hmt In our latest expert interview, Sheila Li shares how customized evaluation frameworks and data‑driven forecasting help pharma teams make confident decisions at every stage of an asset’s journey.

Loss of exclusivity doesn’t have to mean lost opportunity. As pricing pressure rises and markets saturate, forecasting is key to navigating lifecycle transition. Explore our insights: vist.ly/53gji

Silos still limit the impact of competitive intelligence in pharma. Kelly Chamberlain highlights the opportunity: connect qualitative signals with quantitative data, combine human expertise with analytics, and act with confidence. Explore her take: vist.ly/53brs

FDA oversight remains a key factor in orphan drug outlooks. How regulatory assumptions are built into projections through 2032 is discussed in the on‑demand "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: vist.ly/536qt

Will China force drug prices down? Melanie Senior and Andreas Hadjivasiliou address pricing pressure and policy impact in the on‑demand "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: vist.ly/42zw3

From top‑selling drugs to the most valuable pipeline assets, here’s what will shape 2026. Explore the full Preview Report: vist.ly/42spq

By the early 2030s, orphan drugs could make up ~20% of the prescription drug market. What’s driving the forecast? Watch our webinar to find out. "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: vist.ly/42isw

Pharma teams are doing more with less—and CI is evolving. Kelly Chamberlain highlights a shift from tracking everything to focusing on the right signals to assess competitiveness and commercial viability. Read Kelly’s perspective: vist.ly/42e85

China is often cited in discussions on downward pressure on drug prices. Why is it viewed differently? Watch the "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar for insight on pricing across major markets: vist.ly/42drq

Patent expiries are hitting big pharma hard over the next 5 years, with generics and competitors lining up fast. Our latest thought leadership explores how LoE is reshaping forecasting—and how teams can stay ahead. Download the guide: vist.ly/429zr

The projected top 10 orphan drugs in 2032 span diverse diseases, indications, and mechanisms. What does that range say about where the orphan drug market is headed? Watch the on‑demand Orphan "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: vist.ly/423h3

Learn what makes a good (or bad) pharmaceutical forecast model, its importance, and how it aids precise decision-making in this blog post: vist.ly/4zw98

DOWNLOAD: The lines between pharma and biotech are blurring. As funding tightens and policy shifts, biotechs grow leaner and more independent, while pharma explores new models and direct-to-patient channels. Preview the trends in our summary: vist.ly/4zmfv

Join Kelly Chamberlain from Norstella at Pharma CI Europe: Supporting Cross-Functional Teams with Corporate-Level CI • Smarter peer analysis • Reducing bias • Driving strategic value • Sharing insights effectively 📅 Book time: vist.ly/4zh9b

China’s biopharma sector hit a major turning point in 2025 — with rapid R&D growth, expanding therapeutic strength, and accelerated dealmaking reshaping the landscape in 2026. Watch the 2026 Preview on‑demand webinar: vist.ly/4zh3x.

Meet Kelly Chamberlain 👋 Partner of Market Intelligence at @NorstellaCo, she helps pharma teams turn market signals into strategic advantage—blending neuroscience, consulting, and data-driven insight for smarter decisions. Learn more: vist.ly/4zdeh

Many big pharma players are facing patent expiry in the next 5 years, and the pipeline is packed with competitive entrants. This forecasting report examines how the loss of exclusivity (LoE) and generic competition are influencing market planning. vist.ly/4zdec.

For some of the largest pharma companies, orphan drugs could drive ~40% of sales by 2032. What would that level of concentration mean? Watch the "Orphan Drugs: A safe(r) passage amid stormy waters?" on-demand webinar: vist.ly/4zbur